Several compounds based on short chain fatty acids and/or probiotics/prebiotics have shown promising results in the therapy of ulcerative colitis (UC), possibly due to its key role in restoring gut homeostasis as well as intestinal barrier integrity. Here, we investigated the efficacy of a patented preparation based on calcium butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and fructooligosaccharides (FEEDColon®, Princeps, Cuneo, Italy) in maintaining remission and improving subjective symptoms and inflammatory indices in patients with UC receiving 5‐ASA therapy. A total of 42 patients were prospectively recruited and randomized in 21 patients receiving combination therapy with mesalamine (5‐ASA) plus FEEDColon® and 21 patients treated with standard 5‐ASA therapy. Patients were assessed at baseline, at 6‐month, and 12‐month follow‐up (FU). Therapeutic success (defined as Mayo partial score ≤2 and faecal calprotectin (FC) <250 μg/g at 12‐month FU) was reached by 32 (76%) patients: 20 (95%) among those treated with 5‐ASA + FeedColon®, and 12 (57%) among those treated with 5‐ASA only (p = 0.009). Consistently, patients treated with combination therapy improved subjective symptoms (quality of life, abdominal pain, and stool consistency) and reduced FC values, while those treated with 5‐ASA alone, improved neither subjective symptoms nor FC during the FU. In conclusion, FEEDColon® supplementation appears to be a valid add‐on therapy for the maintenance of remission in patients with UC. Further multicentre, placebo‐controlled, double‐blind clinical trials are needed to validate our results on larger cohorts of patients with UC.

Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study

Caviglia G. P.
Co-first
;
De Blasio F.
Co-first
;
Vernero M.;Armandi A.;Rosso C.
;
Saracco G. M.;Bugianesi E.;Astegiano M.;Ribaldone D. G.
Last
2021

Abstract

Several compounds based on short chain fatty acids and/or probiotics/prebiotics have shown promising results in the therapy of ulcerative colitis (UC), possibly due to its key role in restoring gut homeostasis as well as intestinal barrier integrity. Here, we investigated the efficacy of a patented preparation based on calcium butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and fructooligosaccharides (FEEDColon®, Princeps, Cuneo, Italy) in maintaining remission and improving subjective symptoms and inflammatory indices in patients with UC receiving 5‐ASA therapy. A total of 42 patients were prospectively recruited and randomized in 21 patients receiving combination therapy with mesalamine (5‐ASA) plus FEEDColon® and 21 patients treated with standard 5‐ASA therapy. Patients were assessed at baseline, at 6‐month, and 12‐month follow‐up (FU). Therapeutic success (defined as Mayo partial score ≤2 and faecal calprotectin (FC) <250 μg/g at 12‐month FU) was reached by 32 (76%) patients: 20 (95%) among those treated with 5‐ASA + FeedColon®, and 12 (57%) among those treated with 5‐ASA only (p = 0.009). Consistently, patients treated with combination therapy improved subjective symptoms (quality of life, abdominal pain, and stool consistency) and reduced FC values, while those treated with 5‐ASA alone, improved neither subjective symptoms nor FC during the FU. In conclusion, FEEDColon® supplementation appears to be a valid add‐on therapy for the maintenance of remission in patients with UC. Further multicentre, placebo‐controlled, double‐blind clinical trials are needed to validate our results on larger cohorts of patients with UC.
10
21
4961
4966
Complementary therapy; Inflammatory bowel diseases (IBD); Maintaining therapy; Mesalamine; Mesalazine; Short chain fatty acids (SCFAs)
Caviglia G.P.; De Blasio F.; Vernero M.; Armandi A.; Rosso C.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G.
File in questo prodotto:
File Dimensione Formato  
jcm-10-04961-v2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1821050
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact